Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Optiscan Imaging Limited ( (AU:OIL) ) has provided an update.
Optiscan Imaging Limited has initiated a pioneering clinical study in Australia to evaluate the use of its InVue® and InForm™ devices for head and neck cancer surgery. This study, conducted at St John of God Murdoch Hospital in Perth, aims to collect intra-operative imaging data to support FDA submissions and enhance Optiscan’s AI algorithms for oral cancer. The study’s outcomes are expected to improve surgical precision and patient care by providing detailed real-time microscopic insights, potentially revolutionizing treatment approaches for complex head and neck cancers.
More about Optiscan Imaging Limited
Optiscan Imaging Limited operates in the medical imaging industry, focusing on developing advanced imaging devices for precision surgery and digital pathology. Their primary products include the InVue® and InForm™ devices, which are used for real-time imaging in surgical procedures, particularly in the field of oncology.
Average Trading Volume: 193,975
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$120.1M
Learn more about OIL stock on TipRanks’ Stock Analysis page.